Eli Lilly, on the verge of the first consumer ad campaign for its Zepbound weight loss drug ... that people should eat less ...

Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...

Eli Lilly (LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

James Manning - PA Images via Getty Images The move comes after the FDA took tirzepatide, the key ingredient in Eli Lilly’s ...

Eli Lilly's stock valuation sank by $100 billion Wednesday morning after the pharma giant reported third quarter earnings.

The company reported revenue of $11.4 billion and adjusted earnings of $1.18 per share, well below the consensus estimates of $12.1 billion and $1.45, respectively.

Each drug, however, has specific parameters for how they should be used: Ozempic and Mounjaro are for certain Type 2 diabetes patients only, while Wegovy and Zepbound are only for those deemed ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...